How A Vial Of Dirt Became A Longevity Drug

We follow rapamycin from a soil sample on Easter Island to the center of longevity science, then break down how mTOR decides between growth and repair. We also confront the “friendly fire” problem that shows up with chronic dosing and explain why current trials focus on precision pulsing and measurable biomarkers. 
• the 1975 discovery story and why rapamycin was shelved then revived for organ transplantation 
• how TOR genes led to mTOR and why phosphorylation changes protein shape and function 
• mTOR as a nutrient and energy sensor integrating leucine, arginine, ATP, oxygen, and insulin 
• why nonstop mTORC1 activity links to senescence, SASP inflammation, and age-related decline 
• how rapamycin inhibits mTORC1 to unlock autophagy and act as a calorie restriction mimetic 
• what mTORC2 does for cell survival and why losing it can wreck glucose control 
• animal evidence across species including late-life mouse benefits and sex differences 
• why companion dog trials matter and what improved heart function suggests 
• the Fang study logic behind insulin resistance with chronic exposure and later adaptation 
• how human trials use intermittent dosing plus epigenetic clocks, cytokines, metabolic labs, and functional tests 
Keep questioning the world around you. Keep an eye on those clinical trials, and don’t forget to let yourselves take out the trash. 

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Transcript

Easter Island Dirt Discovery

SPEAKER_01 0:00

In 1975, scientists isolated a single vial of dirt from literally one of the most remote places on planet Earth, Easter Island, Rappa Nui.

SPEAKER_00 0:08

Right, right.

SPEAKER_01 0:09

And they were out there looking for um an antifungal compound, like something to just treat simple infections. Athlete's foot, whatever.

SPEAKER_00 0:17

Exactly.

SPEAKER_01 0:18

But instead, what they found buried in that soil was a master biological switch. A switch hidden inside a bacterium that can quite literally command a living cell to stop aging, which is just insane to me.

SPEAKER_00 0:30

Aaron Powell I mean, it sounds completely like science fiction when you frame it like that.

SPEAKER_01 0:33

Aaron Powell It totally does.

SPEAKER_00 0:34

Aaron Powell But the biochemistry backing this up is incredibly concrete. I mean, we are looking at a molecule that interacts with the fundamental infrastructure of how eukaryotic life basically decides whether to grow or whether to hunker down and repair itself.

SPEAKER_01 0:47

Aaron Powell Yeah. And I have been pouring over this giant stack of research you send over for this deep dive. We're talking data from the NIH, uh, the Dog Aging Project, UT Health San Antonio, and it is just staggering.

SPEAKER_00 1:00

Aaron Powell It really is a paradigm shift.

SPEAKER_01 1:01

So our mission today is to completely demystify MTOR signaling, figure out how this drug rapamycin actually works, and look at the clinical trials that are trying to hack the biology of aging. And you know, for everyone listening with us right now, whether you're just trying to figure out how to get a few more healthy years with your golden retriever, or you're tracking your own metabolic health, understanding this specific biological switch is honestly the ultimate shortcut to understanding the entire future of longevity medicine.

SPEAKER_00 1:30

Absolutely. And to really grasp the magnitude of what we're doing in clinical trials today, I think we have to look at the sheer serendipity of that 1975 expedition.

SPEAKER_01 1:39

The dirt expedition.

SPEAKER_00 1:40

The dirt expedition, yes. So Canadian researchers from Ayers Pharmaceuticals were systematically screening soil samples from all around the world.

SPEAKER_01 1:47

Just scooping up dirt everywhere.

SPEAKER_00 1:49

Pretty much. They were looking for novel antibiotics produced by bacteria. And in this particular sample from Rapanui, they isolated a bacterium called Streptomyces hygroscopicus. Streptomyces hygroscopicus, and that bacterium produced a very specific metabolite.

SPEAKER_01 2:04

Which is the magic compound we're talking about today.

SPEAKER_00 2:06

Exactly. A macrolide compound. And because of its origin on Rapanui, they named it Rapamycin.

SPEAKER_01 2:13

Okay, that makes sense.

SPEAKER_00 2:14

And initially, yes, it did kill fungi. But as they started testing it on mammalian cells, the data started coming back with these bizarre anomalies.

SPEAKER_01 2:25

Wait, what kind of anomalies? Like it was killing the mammalian cells too.

SPEAKER_00 2:28

Not killing them, exactly. It was halting their proliferation. It wasn't just targeting fungal pathogens, it was stopping human cells from dividing. It possessed massive, massive immunosuppressive properties.

SPEAKER_01 2:40

Oh, whoa. Which completely derailed its use as an antifungal, right? I mean, you don't want to shut down a patient's entire immune system just to cure athlete's foot.

SPEAKER_00 2:49

You absolutely

From Antifungal To Transplant Drug

SPEAKER_00 2:50

do not. That would be catastrophic.

SPEAKER_01 2:51

Right. Friendly fire.

SPEAKER_00 2:52

Exactly. So the compound was actually just shelved for a while. It wasn't until the 1980s and 90s that the medical community realized its true utility was actually in organ transplantation.

SPEAKER_01 3:03

Oh, because of the immune system thing?

SPEAKER_00 3:05

Yes. If you give a patient a new kidney, their immune system will naturally recognize that kidney as foreign tissue and attack it.

SPEAKER_01 3:13

Because the body is like, hey, this doesn't belong here.

SPEAKER_00 3:15

Precisely. Rapamycin was phenomenal at suppressing that specific immune response, mainly by stopping T cells from dividing. So the FDA eventually approved it as a transplant immunosuppressant.

SPEAKER_01 3:28

But the wild part to me about all of this is that they were prescribing this incredibly powerful drug for years before anyone actually knew how it worked on a molecular level.

SPEAKER_00 3:37

That happens more often than you'd think in medicine, honestly.

SPEAKER_01 3:40

Really? It was just a black box. They were just like, hey, it stops cells from dividing. Let's use it. It wasn't until what

TOR Genes And mTOR Identified

SPEAKER_01 3:45

1991 that the curtain finally got pulled back.

SPEAKER_00 3:47

Yeah, 1991, Michael Hall and his team in Switzerland were studying yeast. Just simple single-celled baker's yeast.

SPEAKER_01 3:54

Just baking bread.

SPEAKER_00 3:55

Right. They exposed the yeast to rapamycin and isolated the specific genes that the drug was targeting. And they called them TOR1 and TOR2 target of rapamycin. And shortly after that, researchers discovered the mammalian equivalent, hence MPOR, the mammalian target of rapamycin.

SPEAKER_01 4:13

Or the mechanistic target of rapamycin, depending on which of these papers you're reading. I saw both terms thrown around a lot.

SPEAKER_00 4:19

Right. I personally prefer mechanistic as it accurately reflects its role across different species. But yes, mammalian is common too.

SPEAKER_01 4:27

Okay, so this is where I think we really have to establish what MTOR actually is biochemically, because it is the absolute linchpin of this entire deep dive.

SPEAKER_00 4:38

It is the core of everything we're discussing.

SPEAKER_01 4:40

The paper called it a serinenthrine protein kinase.

unknown 4:44

Yes.

SPEAKER_01 4:44

Okay, let me stop you there. Because serenanthrinine protein kinase is the exact kind of phrase that makes people's eyes just completely glaze over.

SPEAKER_00 4:52

Fair enough. It is a mouthful.

SPEAKER_01 4:53

I want to make sure we actually explain

How Kinases Physically Flip Switches

SPEAKER_01 4:55

the physics of this to the listener. So a kinase is an enzyme that adds a phosphate group to another molecule, right? Phosphorylation.

SPEAKER_00 5:02

That is the textbook definition, yes.

SPEAKER_01 5:04

But practically, and correct me if I'm visualizing this wrong, adding a phosphate group isn't just like tagging the protein with a sticky note. That phosphate group is highly negatively charged.

SPEAKER_00 5:16

Extremely negatively charged, yes.

SPEAKER_01 5:17

So when a kinase like MTOR slaps a phosphate onto a target protein, that massive negative charge repels other parts of the protein, right? Like magnets pushing away from each other.

SPEAKER_00 5:28

That's exactly what happens.

SPEAKER_01 5:29

Forcing the whole 3D structure of the protein to physically contort and change its shape. It's like putting a bulky padlock on a machine part so it either locks into place or physically just can't fit into the machinery anymore.

SPEAKER_00 5:42

That is a phenomenal way to visualize it. I love that. You are physically altering the topography of the protein so it either activates or deactivates.

SPEAKER_01 5:49

It's mechanical.

SPEAKER_00 5:50

Highly mechanical. And MTOR uses this locking and unlocking mechanism to act as the ultimate sensory integrator for the cell.

SPEAKER_01 5:58

The sensor, like a thermostat.

mTOR As The Cell’s Economy

SPEAKER_00 6:00

More complex than a thermostat. It sits there monitoring the entire environment. It detects amino acids, specifically leucine and arginine from the proteins we eat. It monitors cellular energy levels via ATP. Okay. It detects oxygen levels. It monitors growth factors like insulin. It takes in all this data to make a decision.

SPEAKER_01 6:21

You know, I was trying to come up with an analogy for this because I keep seeing it described as a general contractor in the literature, but that feels a little small to me. I feel like MTOR is more like a national economy.

SPEAKER_00 6:34

A national economy. Okay, I am intrigued. Walk me through the economics of a cell.

SPEAKER_01 6:38

Okay, so imagine MTR is the Federal Reserve and the government rolled into one.

SPEAKER_00 6:42

A powerful entity.

SPEAKER_01 6:43

Right. When times are good, when there's plenty of cash, which is cellular energy, and plenty of raw materials, which are the amino acids, the MTOR shifts the cell into a peacetime boom economy.

SPEAKER_00 6:55

Oh, I see where you're going with this.

SPEAKER_01 6:56

It says build, multiply, synthesize. It drives the creation of new proteins, new lipids, and tells the cells to proliferate. It's the ultimate growth state. Everything is booming.

SPEAKER_00 7:08

I will absolutely adopt that metaphor because it perfectly captures the duality of the system.

SPEAKER_01 7:12

Yeah.

SPEAKER_00 7:13

Definitely. A peacetime boom economy is wonderful for a developing nation, or in biology, a developing human child.

SPEAKER_01 7:22

Because they need to grow.

SPEAKER_00 7:23

Exactly. You want explosive growth. You want to build muscle, bone, and neural tissue. But, and this is the crucial part, what happens to an economy that literally never stops building?

SPEAKER_01 7:33

Never stops.

SPEAKER_00 7:34

Right. If it just keeps producing goods, adding infrastructure, and endlessly consuming resources without ever managing its waste or experiencing a market correction.

SPEAKER_01 7:44

Oh man, you get hyperinflation, you get a massive buildup of useless junk, empty ghost cities, and eventually the whole system just collapses under its own weight.

SPEAKER_00 7:53

Which is precisely what happens in biology when MTOR becomes hyperactive and that peacetime growth state refuses to shut off.

SPEAKER_01 8:01

Whoa. So growth isn't always good.

SPEAKER_00 8:03

Unending growth in an adult organism isn't youth, it's cancer or senescence. We see this in severe pathologies.

SPEAKER_01 8:09

Like what?

SPEAKER_00 8:10

Well, there's a rare progressive lung disease called lamb lymphangioleomyomatosis.

SPEAKER_01 8:16

That's a long word. Lamb.

SPEAKER_00 8:18

Lamb is easier, yes. In lamb, smooth muscle-like cells just endlessly proliferate in the lungs until they form these destructive cysts. It's unchecked growth.

SPEAKER_01 8:28

That sounds awful.

SPEAKER_00 8:29

We also see it in tuberous sclerosis complex, which is a genetic disorder where benign tumors grow in the brain, kidneys, and heart.

SPEAKER_01 8:36

And cancer, obviously, like unregulated growth is the literal definition of cancer.

SPEAKER_00 8:40

Aaron Powell Exactly. Both lamb and tuberosclerosis are actually driven by mutations in

Senescence And The Toxic SASP

SPEAKER_00 8:45

genes that are supposed to inhibit MTR.

SPEAKER_01 8:48

So the breaks are cut.

SPEAKER_00 8:49

The genetic breaks fail, and MTR runs wild. The peacetime economy overheats. And even in healthy adults, chronic unending MTOR activation drives something called senescence.

SPEAKER_01 9:01

Oh, senescence! That is fascinating. I was reading about that. It's when a cell basically reaches the end of its useful life, it stops dividing, but it refuses to die. It just sits there like a zombie.

SPEAKER_00 9:12

A very toxic zombie. Right. Senescence cells aren't just inactive, they secrete a cocktail of inflammatory cytokines, chemokines, and protestases. We call it the SASP, the senescence associated secretory phenotype. This chronic, low-grade inflammation actually degrades the surrounding healthy tissue. It's a primary driver of the aging process itself.

SPEAKER_01 9:32

So the goal isn't just to grow forever. We actually need the economy to occasionally experience a recession. We need to stop building. Yes. Which brings us to the structure of MTR

mTORC1 Shuts Off Autophagy

SPEAKER_01 9:41

itself. Because as I was reading the UT Health papers, I realized MTR isn't just one monolithic entity. It operates in two entirely different complexes, two different crews running the economy.

SPEAKER_00 9:51

MTORC1 and MTORC2.

SPEAKER_01 9:54

Right.

SPEAKER_00 9:54

And understanding the division of labor between these two complexes is the only way to understand both the promise and the danger of rapamycin.

SPEAKER_01 10:02

Okay, let's break down the first crew, MTORC1.

SPEAKER_00 10:05

So MTORC1 is defined by the presence of a specific scaffolding protein called Raptor.

SPEAKER_01 10:10

Raptor. Like the dinosaur.

SPEAKER_00 10:12

Sure, like the dinosaur. This is the complex that acts as the peacetime economy you described.

SPEAKER_01 10:16

Got it.

SPEAKER_00 10:17

It is acutely sensitive to nutrients. Yep. And crucial to our deep dive today, it is acutely sensitive to rapamycin.

SPEAKER_01 10:23

And when we say sensitive, we mean rapamycin physically jams the gears of this specific complex.

SPEAKER_00 10:29

It creates a wedge. Rapamycin enters the cell and binds to a small protein called FKBP12.

SPEAKER_01 10:34

Okay, rapamycin grabs this little FKBT12 protein.

SPEAKER_00 10:37

Yes. And this new rapamycin FKBP12 complex then physically docks onto MTORC1 right next to the kinase domain, effectively blinding it. It physically blocks the substrates from accessing the active site. The padlock. Exactly. It locks it down.

SPEAKER_01 10:52

So the peacetime economy is artificially shut down by this drug.

SPEAKER_00 10:55

Shut down instantly. And the downstream effects of this are profound. When MTORC1 is active, it normally promotes translation, the making of new proteins by phosphorylating targets like N6K1 and 4EBP1.

SPEAKER_01 11:07

Okay, wait. The 4E BP1 interaction is brilliant. Let me see if I have this right.

SPEAKER_00 11:11

Go ahead.

SPEAKER_01 11:12

From what I understand, 4EBT1 is normally a suppressor. Like it wraps around the protein making machinery and stops it. But when MTORC1 phosphorylates it, when it adds that bulky negative phosphate group we talked about, it forces 4EBP1 to change shape and release its grip, which allows the cell to suddenly manufacture new proteins.

SPEAKER_00 11:32

That is the exact mechanical reality, yes.

SPEAKER_01 11:35

It's so cool.

SPEAKER_00 11:36

It really is. But more important for our discussion on aging is what MTORC1 does to catabolic processes.

SPEAKER_01 11:42

Catabolic meaning breaking things down, right?

SPEAKER_00 11:45

Yes, breaking down molecules. When MTRC1 is running the boom economy, it puts a hard physical break on a process called autophagy.

SPEAKER_01 11:52

Autophagy, literally self-eating, if you look at the green.

SPEAKER_00 11:55

Yes. And returning to your economic metaphor, if MTORC1 is peacetime consumerism, autophagy is the wartime rationing economy.

SPEAKER_01 12:03

Ooh, I like that.

SPEAKER_00 12:04

When resources are incredibly scarce, a nation stops building new shopping malls and starts melting down old cars and scrap metal to build tanks.

SPEAKER_01 12:11

It recycles from within.

SPEAKER_00 12:13

Exactly. It uses its own garbage as fuel.

SPEAKER_01 12:15

I love that. So instead of just leaving all the misfolded proteins and damaged cellular machinery lying around, the cell builds these little molecular garbage bags, what I call autophagosomes.

SPEAKER_00 12:25

Autophagosomes, yes.

SPEAKER_01 12:26

And it sweeps it all up, melts it down, and uses the raw amino acids to survive.

SPEAKER_00 12:31

And the mechanical way MTRRC1 stops this is by phosphorylating two initiation proteins called ULK1 and ATG13.

SPEAKER_01 12:38

More padlocks.

SPEAKER_00 12:39

More padlocks. By placing those phosphate padlocks on the initiation proteins, MTORC1 physically prevents the autophagus and garbage bags from ever forming. The wartime recycling factories are basically padlocks shut.

SPEAKER_01 12:52

Which is fine when you're young and healthy and flooded with nutrients. But as we age, if we never flip that switch, the cellular scrap metal just piles up.

SPEAKER_00 13:00

It accumulates relentlessly.

SPEAKER_01 13:02

Just trash everywhere in the cell.

SPEAKER_00 13:03

Literally. We see a buildup of misfolded proteins and highly dysfunctional exhausted mitochondria. This accumulation underpins age-related cellular failure across the board.

SPEAKER_01 13:13

Like neurodegenerative diseases.

SPEAKER_00 13:15

Precisely. Alzheimer's is characterized by amyloid beta plaques and tautangles. Parkinson's involves alpha-cinuclein aggregation.

SPEAKER_01 13:23

Oh wow.

SPEAKER_00 13:23

These are all toxic proteins that a robust autophagic system should theoretically clear out.

SPEAKER_01 13:28

Okay, so here is the absolute genius of rapamycin, then. If you give a cell rapamycin, it binds to that FKBP12 protein, wedges into MTORC1, and shuts it down. Yes. And because MTORC1 is shut down, the bulky phosphate padlocks are removed from ULK1 and ATG13.

SPEAKER_00 13:48

To break her off.

SPEAKER_01 13:49

The itophagosomes form. The cell suddenly switches into the wartime rationing economy and starts melting down the toxic amyloid plaques and broken mitochondria, even though the body isn't actually starving.

SPEAKER_00 14:01

It is the ultimate biochemical trick.

SPEAKER_01 14:03

Dude, that is wild.

SPEAKER_00 14:04

It is a calorie restriction mimetic.

SPEAKER_01 14:06

Mimetic. So it mimics calorie restriction.

Rapamycin Mimics Calorie Restriction

SPEAKER_00 14:09

Yes. You get the profound cellular repair benefits of starvation without the physiological trauma of actual famine.

SPEAKER_01 14:15

Okay. That is just incredible. But so that's the peacetime crew, MTORC1. You mentioned a second complex, MTORC2.

SPEAKER_00 14:22

Yes, the other side of the coin.

SPEAKER_01 14:23

Now from what I read, this is where the whole anti-aging narrative hits a massive wall of complication.

SPEAKER_00 14:28

A very steep wall.

mTORC2 Keeps Cells Metabolically Stable

SPEAKER_00 14:29

MTORC2 is the structural maintenance crew. It contains a different core protein called Richter rather than Raptor.

SPEAKER_01 14:34

Raptor and Richter. Okay.

SPEAKER_00 14:36

Yes. And its primary job is not nutrient sensing, it regulates the actin cytoskeleton, which is the physical scaffolding that gives a cell its shape, and it promotes cellular survival by activating a downstream kinase called act.

SPEAKER_01 14:49

So it's keeping the physical house from falling down.

SPEAKER_00 14:52

Exactly.

SPEAKER_01 14:53

And rapamycin doesn't wedge into MTORC2.

SPEAKER_00 14:57

It does not. The Richter protein physically blocks the rapamycin FKBP12 complex from binding. Oh. So acutely, rapamycin only shuts down the boom economy of MTORC1 while leaving the vital survival scaffolding of MTRC2 completely operational.

SPEAKER_01 15:13

That sounds like a perfect drug. You turn on the recycling, clear out the Alzheimer's proteins, and keep the cellular scaffolding strong.

SPEAKER_00 15:19

In theory, yes.

SPEAKER_01 15:20

Which totally explains why the animal trials I looked at were so overwhelmingly positive.

Lifespan Wins In Animal Studies

SPEAKER_01 15:25

I mean, they didn't just test this in a petri dish, they put it in basically every model organism we have.

SPEAKER_00 15:30

The evolutionary conservation of the MTR pathway is staggering.

SPEAKER_01 15:33

It's the same switch in everything.

SPEAKER_00 15:35

Practically, Rapamyxin extends the lifespan of yeast, it extends the lifespan of C. elegans, the microscopic nematode worms, it works in Drosophila, the fruit flies, and then, of course, the mammalian trials.

SPEAKER_01 15:48

The 2009 Harrison study from the interventions testing program, I spent a lot of time on this paper because it seems like the moment the longevity community just went into absolute overdrive.

SPEAKER_00 15:58

It was a huge paradigm shift. Before 2009, the idea of a pharmacological intervention reliably extending mammalian lifespan was highly speculative.

SPEAKER_01 16:07

Just a pipe dream.

SPEAKER_00 16:08

Exactly.

SPEAKER_01 16:08

And the methodology of that study is what makes it so bulletproof, right? Because they didn't just use those highly inbred lab mice where one weird genetic cork could skew all the data.

SPEAKER_00 16:18

No, they used genetically heterogeneous mice.

SPEAKER_01 16:20

Which mimic the messy genetic diversity of a human population.

SPEAKER_00 16:24

Precisely.

SPEAKER_01 16:24

And more importantly, they didn't start feeding them rapamycin when they were pups.

SPEAKER_00 16:28

This is the critical detail. They started the intervention when the mice were 20 months old.

SPEAKER_01 16:32

And in marine physiology mouse years, 20 months is roughly equivalent to a 60-year-old human. That is the part that genuinely stopped me in my tracks. You take a mouse that is already entering its senior years, you start giving it rapamycin, and it still significantly extends both the median and maximal lifespan.

SPEAKER_00 16:52

It's quite profound.

SPEAKER_01 16:53

It's not just preventative if you start at birth, it's practically restorative late in life.

SPEAKER_00 16:59

It delayed age-related decline across multiple organ systems, it preserved liver function, maintained tendon elasticity, mitigated cardiac hypertrophy.

SPEAKER_01 17:08

That's insane.

SPEAKER_00 17:09

However, you noted some nuances in the ITP data when you were reviewing the materials earlier.

SPEAKER_01 17:14

Oh, yeah. The sex differences really stood out to me. When you look at the lifespan curves, rapamycin works in both sexes, but the lifespan extension is noticeably more pronounced in female mice than in male mice.

SPEAKER_00 17:25

Yes, that's accurate.

SPEAKER_01 17:26

And then you compare that to another drug the ITP tested, uh 17 alpha estradiol, which extended lifespan only in male mice and did absolutely nothing for females. Right. So are we looking at a hormonal interference with MTOR, or do male and female livers just metabolize the drug differently?

SPEAKER_00 17:44

That is a highly sophisticated question, honestly. And the answer is likely pharmacokinetic.

SPEAKER_01 17:48

Pharmacokinetic, so how the drug moves through the body.

SPEAKER_00 17:51

Right. Female mice seem to maintain higher blood levels of rapamycin than males given the exact same dose in their shell. They simply clear the drug from their systems more slowly.

SPEAKER_01 18:02

Oh, so they just have more of it in their bloodstream.

SPEAKER_00 18:05

Essentially, yes. But the broader point is critical. Aging pathways are often sexually dimorphic.

SPEAKER_01 18:12

Dimorphic, meaning two different forms.

SPEAKER_00 18:14

Yes. What works for a male biology may not perfectly map onto a female biology, which makes translation to human trials incredibly complex.

SPEAKER_01 18:23

Which perfectly brings me to the intermediate step between mice and humans, the

Dog Aging Project And Heart Data

SPEAKER_01 18:28

dogs.

SPEAKER_00 18:28

Ah, yes, dogs.

SPEAKER_01 18:30

I am obsessed with the dog aging project.

SPEAKER_00 18:32

It's a remarkable initiative, primarily driven by the University of Washington and Texas AM.

SPEAKER_01 18:36

Dr. Kate Creevy and her team, they just got a $7 million NIH grant for the Tri-Aid trial.

SPEAKER_00 18:42

The test of rapamycin in aging dogs.

SPEAKER_01 18:44

Yes. And what's brilliant about this is that they aren't locking a bunch of beagles in a sterile lab. They are enrolling 580 companion dogs, pet dogs, living in normal homes, sleeping on couches, eating dropped food off the kitchen floor.

SPEAKER_00 19:00

The environmental variable is crucial here. Lab mice live in a pathogen-free, temperature-controlled, perfectly regulated bubble.

SPEAKER_01 19:09

Yeah. Real life is messy.

SPEAKER_00 19:10

Exactly. Companion dogs share our environment. They drink our water. They're exposed to the same ambient pollutants. They share our circadian disruptions.

SPEAKER_01 19:20

They stay up late with us.

SPEAKER_00 19:21

They do. And biologically, they age in ways that perfectly mirror human decline. They develop osteoarthritis, they suffer from cardiac stiffening, they even experience canine cognitive dysfunction.

SPEAKER_01 19:32

Which is functionally very similar to human dementia.

SPEAKER_00 19:34

Yes, it is.

SPEAKER_01 19:35

And because a large breed dog naturally only lives 10 to 12 years, you can actually run a clinical trial and see the results in a reasonable time frame. You don't have to wait 80 years. I was reading the pilot study data they published before Triad, where they gave low intermittent doses of rapamycin to a small cohort of middle-aged dogs. The cardiac data was incredible. It improved fractional shortening.

SPEAKER_00 19:58

Right. Let's define fractional shortening so the listeners understand what that implies.

SPEAKER_01 20:02

Okay. From my understanding, fractional shortening is the percentage of blood the left ventricle of the heart pumps out with every single contraction. Yes. As mammals get older dogs and humans, the heart muscle gets thicker, stiffer, and less elastic. It turns into an old rubber band.

SPEAKER_00 20:17

Aaron Powell A very apt description.

SPEAKER_01 20:19

It can't fully relax between beats to fill with blood, which is diastolic dysfunction, but rapamycin seemed to physically reverse that stiffening in the dogs.

SPEAKER_00 20:28

It restored the elasticity of the myocardium. The heart could pump more efficiently.

SPEAKER_01 20:32

That's basically giving them puppy hearts back.

SPEAKER_00 20:34

In a sense, yes. And we are seeing similarly promising safety profiles in non-human primate studies.

SPEAKER_01 20:41

Oh, the monkeys.

SPEAKER_00 20:42

Yes. There is an ongoing trial with 66 middle-aged marmoset monkeys receiving rapamycin in their diet. So far, the toxicity is practically non-existent at the doses used, with only minor shifts in metabolic markers.

SPEAKER_01 20:56

Okay, so let's just pause for a second and look at the scoreboard here.

SPEAKER_00 20:59

Let's hear it.

SPEAKER_01 21:00

We have yeast, worms, and flies living longer. We have 60-year-old equivalent mice becoming incredibly resilient. We have pet dogs getting more elastic hearts. We have monkeys tolerating it perfectly. The wartime recycling economy of autophagy works. It does. So I am going to ask the obvious, slightly chaotic question: why is this not in the water supply?

Why Chronic Dosing Causes Friendly Fire

SPEAKER_01 21:23

Why aren't we all taking a daily pill of rapamycin with our morning coffee?

SPEAKER_00 21:27

Because of the Fang study.

SPEAKER_01 21:28

Ah, yes. The Fang study. This is where the story gets incredibly dark.

SPEAKER_00 21:31

Aaron Powell I wouldn't call it dark. I would call it a profound lesson in the arrogance of pharmacology.

SPEAKER_01 21:36

Okay, fair.

SPEAKER_00 21:36

Remember when we said that rapamycin is acutely specific to MTORC1? Yeah. And that it leaves the structural survival crew MTORC2 completely alone?

SPEAKER_01 21:45

Right, because the Richter protein physically blocks it from binding.

SPEAKER_00 21:49

That remains true for the intact MTORC2 complex.

SPEAKER_01 21:53

Intact. Key word.

SPEAKER_00 21:54

But if you dose an animal chronically, if you flood their system with rabamycin every Every single day at high doses. You initiate what you so aptly described earlier as friendly fire.

SPEAKER_01 22:05

Walk me through the physics of the friendly fire because this is the catch.

SPEAKER_00 22:09

This is the massive catch. The cell is constantly degrading old proteins and synthesizing new ones, including new MTR molecules. Right. When rapamycin enters the cell, it binds to that FKBP12 protein and that combined unit seeks out free MTR molecules to shut down MTORC1.

SPEAKER_01 22:25

Okay.

SPEAKER_00 22:25

If you constantly flood the cell with rapamycin, it acts like a sponge, sequestering every single newly synthesized free MTOR molecule floating in the cytoplasm.

SPEAKER_01 22:34

Oh wow. So it's like stealing all the lumber before the second crew can even build the house. When the cell realizes it needs to build a new MTORC2 scaffolding complex, it reaches into the toolbox for the core MTRR protein, and the toolbox is completely empty.

SPEAKER_00 22:49

Precisely. Rapamycin stole all the parts. You have starved the supply chain. Over a period of chronic exposure, the existing MTORC2 complexes degrade naturally, and the cell physically cannot assemble replacements.

SPEAKER_01 23:03

So you have now inadvertently shut down both MTORC1 and MTORC2. Exactly. And shutting down MTORC2 is a metabolic disaster. I was reading the Fang and colleagues paper, and the data is honestly terrifying if you're looking at this as a longevity biohacker.

SPEAKER_00 23:19

It is sobering data.

SPEAKER_01 23:21

They gave male mice continuous rapamycin, and within two weeks, the mice developed severe glucose intolerance and insulin resistance. They basically induce type 2 diabetes in a fortnight.

SPEAKER_00 23:30

And hyperlipidemia, spiking cholesterol, and triglyceride levels. It is the exact opposite of a healthy metabolic profile.

SPEAKER_01 23:36

How does shutting down the scaffolding crew cause diabetes? I'm trying to wrap my head around that.

SPEAKER_00 23:41

It comes down to a highly complex, almost counterintuitive feedback loop involving a protein called IRS-1.

SPEAKER_01 23:47

IRS-1, insulin receptor substrate one.

SPEAKER_00 23:50

Yes. Let's trace the wiring here. Under normal, healthy conditions, when MTORC1 is active and building the peacetime economy, it needs a way to tell the rest of the cell, hey, we have enough resources, stop absorbing more.

SPEAKER_01 24:02

Makes sense.

SPEAKER_00 24:03

It does this by phosphorating and actively degrading IRS-1.

SPEAKER_01 24:07

So it's a negative feedback loop, a shutoff valve.

SPEAKER_00 24:10

Exactly. Now when you introduce rapamycin and crush MTORC1, you remove that negative feedback. IRS-1 is no longer degraded.

SPEAKER_01 24:18

It builds up.

SPEAKER_00 24:19

It builds up massively. And this accumulation of IRS-1 hyperactivates an upstream signaling pathway called PI3K.

SPEAKER_01 24:26

Wait, wait, I think I followed this. So PI3K is screaming at the pancreas that the cell needs more insulin, causing insulin levels to spike massively to handle the glucose, which eventually burns out the receptors and causes insulin resistance.

SPEAKER_00 24:39

That is the exact mechanical cascade. You pull the lever to stop the cellular trash buildup via autophagy, and the insulin factory suddenly goes completely haywire.

SPEAKER_01 24:47

Friendly fire.

SPEAKER_00 24:48

And the importance of MTORC2 for male longevity specifically cannot be overstated. If you look at genetic knockout studies, where scientists engineer male mice to be born completely lacking the Richter protein, meaning they have zero MTORC2 function, those mice actually live shorter lives.

SPEAKER_01 25:07

Shorter. So hitting MTORC2 is undeniably toxic.

SPEAKER_00 25:10

Undeniably.

SPEAKER_01 25:11

But then the Fang study gets even weirder, right? Because they didn't stop the trial at two weeks when the mice got diabetes. They kept forcing the mice to take rapamycin.

SPEAKER_00 25:20

Yes, they maintained the chronic dosing protocol. And around the six-week mark, the physiology began to transition. Okay. By 20 weeks of continuous rapamycin exposure, the insulin levels dropped back down, and the mice actually showed improved insulin sensitivity compared to the control group.

SPEAKER_01 25:36

Well, it caused diabetes and then it effectively cured the diabetes it caused. That makes absolutely zero sense.

SPEAKER_00 25:41

I know, it sounds contradictory. But it makes perfect sense if you view the body as an infinitely adaptable homeostatic machine. Right. The initial shock of MTORC2 starvation caused a metabolic crisis. But over 20 weeks, the body downregulated other receptors, shifted its metabolic pathways, and adapted to the new biochemical reality.

SPEAKER_01 26:04

It just figured out a workaround.

SPEAKER_00 26:06

Eventually settling into a hyperefficient insulin-sensitive state, yes.

SPEAKER_01 26:09

Okay, but as a human being, I don't want to spend 20 weeks in a diabetic state hoping my body figures out a workaround.

SPEAKER_00 26:15

No sensible physician would ever recommend that. Which is why the holy grail of this entire field is developing a protocol or a new molecule that perfectly isolates MTORC1 without ever bleeding over into MTORC2.

SPEAKER_01 26:29

Right. I saw a paper by Cameron and colleagues talking about trying to design drugs around the Crim domain of SIN1.

SPEAKER_00 26:35

Yes, SIN1.

SPEAKER_01 26:36

What exactly is SYN1?

SPEAKER_00 26:37

SIN1 is another structural component of the MTORC2 complex. The Crim domain, which stands for conserve region in the middle, is the specific physical latch that MTRC2 uses to grab onto and activate its targets, like the ACE survival kinos.

SPEAKER_01 26:50

So if we can target the Crim domain, we can control MTORC2 directly. But the paper pointed out that most of the pharmaceutical funding for this is coming from cancer research, not longevity research.

SPEAKER_00 27:01

That is the bottleneck.

SPEAKER_01 27:03

And in cancer, they want the exact opposite outcome. A tumor relies heavily on MTORC2 to survive and vascularize. So oncologists are trying to design small molecules that block the crim domain to kill the scaffolding crew.

SPEAKER_00 27:17

That's the tragic irony of the funding structure right now. Billions of dollars are being poured into dual MTOR inhibitors for oncology.

SPEAKER_01 27:25

Drugs designed to ruthlessly crush both MTORC1 and MTRC2.

SPEAKER_00 27:30

Exactly. But for geroscience, the study of aging, we desperately need a drug that guarantees MTORC2 remains 100% operational. We need a pure unadulterated MTORC1 inhibitor.

SPEAKER_01 27:42

And since we don't have that perfect magical molecule yet, we have to rely on dosing strapper geese. Which brings us to the human clinical trials happening right now.

Human Trials Focus On Pulsing

SPEAKER_00 27:50

Finally, we are moving out of the era of speculative internet forum biohacking and into rigorous NIA-funded clinical validation.

SPEAKER_01 27:57

Yes. Dr. Ellen Craig and Dr. Dean Kellogg at UT Health San Antonio are at the forefront of this.

SPEAKER_00 28:02

They are.

SPEAKER_01 28:02

They are running a trial with 84 healthy older adults, ages 65 to 90, and the entire premise of the trial is precision dosing.

SPEAKER_00 28:11

Precision intermittent dosing. The logic is elegant, honestly. If chronic exposure starves the cell of free MTOR and destroys MTORC2, the solution is simply to not expose the cell chronically.

SPEAKER_01 28:25

You pulse it.

SPEAKER_00 28:26

You pulse it. They are testing regimens like one milligram per day for a very short duration of eight weeks, or a single five milligram dose given just once a week.

SPEAKER_01 28:35

Okay, so walk me through what happens in the body when you pulse it like that. So you flood the system on a Monday.

SPEAKER_00 28:40

Right, Monday morning. The rapamycin hits MTOR-C1 hard, the boom economy shuts down, the bulky phosphate padlocks come off ULK1 and ATG13.

SPEAKER_01 28:49

Autophagy kicks into high gear.

SPEAKER_00 28:50

Yes. And the cellular garbage trucks roll out to clear up the misfolded proteins. But then, because you don't take another pill on Tuesday or Wednesday, the drug clears out of the bloodstream.

SPEAKER_01 29:00

It clears out before it has the chance to sequester enough free MTOR to disrupt the assembly of the MTOR-C2 scaffolding.

SPEAKER_00 29:06

That's exactly it. The patient gets the profound autophagic repair benefits of MTORC1 inhibition, completely dodging the hypolipidemia and insulin resistance of MTOR-C2 inhibition.

SPEAKER_01 29:19

That is incredible. And there's precedent for this working in humans, right? I read about a trial using a topical 8% rapamycin cream on the skin.

SPEAKER_00 29:28

A phenomenal localized study.

SPEAKER_01 29:29

Because by applying it topically, they avoided systemic metabolic issues entirely.

SPEAKER_00 29:34

Yes. And the skin biopsy showed a definitive reduction in markers of cellular senescence. The SASP was suppressed. The skin was, at a biological level, acting younger. Just from a cream. Furthermore, previous short-term, low-dose systemic trials in older cohorts demonstrated zero clinically relevant adverse cognitive or immune side effects. Well, this is where dose makes the poison. At massive daily doses for a transplant patient, yes, it paralyzes T cell proliferation. But at a low intermittent dose, a derivative of rapamycin, called a Rapolog, actually improved the immune response of elderly patients to a seasonal influenza vaccine.

SPEAKER_01 30:20

Shut up. It made their immune system sharper.

SPEAKER_00 30:22

It rejuvenated hematopoietic stem cell function.

SPEAKER_01 30:25

I am mind-blown.

SPEAKER_00 30:26

By clearing out the senescent garbage in the immune compartments via autochogy, the remaining immune cells were more robust, functional, and responsive to the vaccine antigen.

SPEAKER_01 30:36

Okay, that completely blows my mind. But I do have a really pragmatic question about these human trials.

SPEAKER_00 30:40

Sure.

Biomarkers That Track Biological Age

SPEAKER_01 30:41

When Dr. Craig and Dr. Kellogg are running this study at UT Health, how do they actually know if it's working? You can't run a human lifespan trial.

SPEAKER_00 30:49

No, you can't.

SPEAKER_01 30:49

It would take 80 years and cost $3 billion to see who lives longer. Are they just like seeing if an 80-year-old can walk up a flight of stairs faster?

SPEAKER_00 30:58

Functional metrics like grip strength and gate speed are tracked. Yes, they're important. But to truly measure the efficacy of a longevity intervention in a realistic time frame, the field relies on biomarkers of aging.

SPEAKER_01 31:10

Biomarkers.

SPEAKER_00 31:11

We are measuring the molecular footprints of decay.

SPEAKER_01 31:14

Like the epigenetic clocks? I keep hearing about those.

SPEAKER_00 31:17

Epigenetic clocks are currently the gold standard. We analyze DNA methylation patterns. Over time, certain regions of your DNA accumulate methyl groups, which actually changes how your genes are expressed. Okay. By analyzing these patterns, we can determine the biological age of your cells, which might be very different from your chronological age.

SPEAKER_01 31:36

So you could be chronologically 75, but if the rapamycin pulsing is working, your DNA methylation clock might read 68.

SPEAKER_00 31:43

That is the goal. We also heavily monitor the metabolic markers we discussed earlier, ensuring insulin sensitivity remains stable or improves.

SPEAKER_01 31:52

To make sure we aren't hitting MTORC2.

SPEAKER_00 31:54

Exactly. We run comprehensive cytokine panels in the blood to look for reductions in IL6 and TNF alpha, which proves we are successfully suppressing that toxic SSP from the senescent cells. Got it. And borrowing directly from the dog aging project, we measure cardiac fractional shortening via echocardiogram to track the physical elasticity of the myocardium in humans.

SPEAKER_01 32:16

We are literally trying to prove that the biological odometer of a human being is rolling backward even while the calendar keeps moving forward.

SPEAKER_00 32:24

We are decoupling chronological time from biological decay.

SPEAKER_01 32:27

This entire journey is just it's a testament to how wild science actually is. I mean, let's just trace the exact through line here.

SPEAKER_00 32:35

Let's do it.

SPEAKER_01 32:36

It starts in 1975 with a handful of dirt from Easter Island. Rapin Nui. A team looking for athlete's foot medicine accidentally discovers rapamycin. That molecule leads scientists to identify MTOR, this ancient conserved master switch that acts as the economic engine for every eukaryotic cell on Earth.

SPEAKER_00 32:55

A switch that integrates the availability of amino acids, ATP, oxygen, and insulin to dictate whether a cell builds or whether it repairs.

SPEAKER_01 33:02

Right. And we figured out that while the boom economy of MTORC1 is great for building muscle, if you let it run forever, it shuts down the garbage trucks. It stops autophagy.

SPEAKER_00 33:10

The amyloid plaques build up, the mitochondria burn out, and we age.

SPEAKER_01 33:15

But by pulsing rapamycin, we can wedge the gears of MTORC1, take off those phosphate padlocks, and trigger that wartime rationing economy where the cell melts down its own toxic waste to survive.

SPEAKER_00 33:27

And we observe this working spectacularly across species: yeast, nematodes, flies.

SPEAKER_01 33:32

The genetically diverse mice in the 2009 Harrison study starting at 60 human years old, the companion dogs in the triad trial regaining heart elasticity, the marmoset monkeys all pointing to massive lifespan and health span extension.

SPEAKER_00 33:45

But then the reality check.

SPEAKER_01 33:47

The reality check. The friendly fire.

SPEAKER_00 33:49

Chronic exposure, sequesters-free MTOR, preventing the assembly of the MTRR-C2 structural complex.

SPEAKER_01 33:56

Which rips away the negative feedback loop on IRS-1, spikes the PI3K pathway, and drops the mice straight into insulin resistance and diabetes, a catastrophic metabolic cost.

SPEAKER_00 34:06

And so the absolute cutting edge of human science right now, the UT health trials, is the delicate art of precision dosing.

SPEAKER_01 34:11

Get in, shut down the boom economy, trigger autophagy, and get the drug out of the system before the scaffolding crew starves.

SPEAKER_00 34:17

It is a remarkable summary of a staggeringly complex biological cascade. And to bring this out of the laboratory and back to the listener, I think it's vital to realize that understanding MTOR is not just an academic exercise while we wait for a

Diet Protein Fasting And mTOR

SPEAKER_00 34:33

prescription.

SPEAKER_01 34:33

No, definitely not.

SPEAKER_00 34:34

This biochemistry dictates your daily life. It explains the mechanics of your diet.

SPEAKER_01 34:40

Because amino acids trigger MTOR.

SPEAKER_00 34:42

Specifically, leucine, found in high concentrations in animal protein, is a potent activator of MTOR C1.

SPEAKER_01 34:50

Ah. This explains why hyper-high protein diets are excellent for building muscle in the short term, like for bodybuilders, but might be detrimental to long-term longevity if they never sell MTOR to rest.

SPEAKER_00 35:02

Exactly. It also provides the exact mechanical explanation for why intermittent fasting is biologically effective.

SPEAKER_01 35:08

Because fasting naturally depletes the amino acids and the cellular energy. It physically removes the cash from the economy, which naturally shuts down MTORC1, which naturally removes the break on ULK1, and naturally turns on autophagy.

SPEAKER_00 35:22

You got it perfectly.

SPEAKER_01 35:23

Fasting is basically doing exactly what rapamycin does. You just have to actually endure the hunger to get there.

SPEAKER_00 35:29

Diet, metabolism, and the rate at which you age are all speaking the exact same chemical language.

SPEAKER_01 35:35

It fundamentally changes how you look at a meal or a workout or even just a missed night of sleep. It's all just inputs into this master switch. Okay, well, before we wrap this up, you have a habit of dropping these massive perspective shifting thoughts at the end of our discussions.

SPEAKER_00 35:50

I try my best.

SPEAKER_01 35:51

Where does this all ultimately lead?

The Big Question About Curing Aging

SPEAKER_00 35:54

Well, if you extrapolate the trajectory of this research, whether it's precision rapamycin dosing or a future molecule targeting the crumb domain that perfectly isolates MTORC1, it raises a deeply profound philosophical question.

SPEAKER_01 36:07

Aaron Powell Okay, I'm ready.

SPEAKER_00 36:08

Right now, this intervention works by tricking the cell into a state of famine. It activates ancient evolutionary repair mechanisms that were specifically designed to keep us alive during starvation.

SPEAKER_01 36:19

Right. We are hacking a survival response.

SPEAKER_00 36:21

Aaron Powell But if juroscience perfects this, if we create a daily protocol that continually initiates ultimate cellular repair without a human being ever having to experience true starvation, disease, or the accumulation of metabolic waste, how does that change the fundamental human experience? Oh wow. If the autophagic recycling is perfectly optimized and the senescent SASP never sets in to degrade our tissues, do we have to completely rewrite our definition of a normal lifespan?

SPEAKER_01 36:52

That is heavy.

SPEAKER_00 36:54

Have we just assumed aging is an inevitable law of physics when in reality it is simply a biochemical disease that we finally learned how to cure?

SPEAKER_01 37:02

We just needed the instruction manual. And it was buried in the birth on an island in the middle of the Pacific. That is absolutely incredible. Thank you for walking through this massive stack of research with me today.

SPEAKER_00 37:11

It was my pleasure.

SPEAKER_01 37:12

And to everyone listening, keep questioning the world around you. Keep an eye on those clinical trials, and don't forget to let yourselves take out the trash. We will see you next time.